China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

Akeso has received approval from China's NMPA for gumokimab to treat adults with moderate-to-severe plaque psoriasis. The approval is based on data from one pivotal Phase III study (AK111-301) and three additional supportive studies. At week 12, gumokimab achieved PASI 75 of 94.6% and PASI 100 of 47.7%, versus 28.6%. Credit: PanuShot / Shutterstock.com. Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis. The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. LOA and…

Source: Pharmaceutical Technology